Vaxcyte Prices $550M Public Offering

Vaxcyte, a clinical-stage vaccine innovation company, has commenced an underwritten public offering of 11 million shares of common stock at $50.00 per share, aiming to raise $550 million in gross proceeds. The company also granted underwriters a 30-day option to purchase an additional 1.65 million shares. This offering, which includes common stock and pre-funded warrants, is scheduled to close on February 2, 2026. Bank of America===Bank of America, Jefferies, SVB Financial Group===Leerink Partners, Evercore===Evercore, and Guggenheim Partners===Guggenheim Partners are serving as joint book-running managers, with Mizuho, BTIG, and Needham & Company also involved. Vaxcyte is developing several vaccine candidates, including VAX-31 and VAX-24 for pneumococcal disease, utilizing its XpressCF platform. Analysts maintain a 'Strong Buy' consensus, and the company's stock has seen a 51.69% return over the past six months.